mortality rates have been projected to increase for males from 9.0/100,000 persons in 2014 to 11.8/100,000 persons in 2025; and for females, from 3.8/100,000 persons to 4.9/100,000 persons. 6 The disease burden associated with HCC is highest in areas with endemic hepatitis B (HBV) (i.e. HBsAg prevalence > 6%), such as in sub-Saharan Africa and Asia, with HCC incidence rates of over 20 per 100,000 individuals. [7] [8] [9] In regions of high incidence, the most common cause is HBV transmitted at birth, i.e. vertical transmission. In comparison to North American and European populations -where the most common aetiology is hepatitis C (HCV) acquired later in life -diagnosis of HCC occurs approximately one decade earlier among populations with prevalent vertical transmission. 9, 10 For example, the mean age interval at diagnosis of HCC in China is 55 to 59 years; in Europe and North America this range is 63 to 65 years, and among low-risk populations 75+ years. 10 HCC is more common in men than women as HBV, HCV, and alcohol consumption are more prevalent and possibly more carcinogenic in males. 11 In 80 to 90% of cases, most (70-90%) HBVrelated HCC develops in cirrhotic livers. 12 Cirrhosis due to HBV or HCV is the leading risk factor for HCC: in 80 to 90% of cases, HCC occurs in the setting of cirrhosis. 13 The
Increasing incidence and mortality related to liver cancer in Australia: time to turn the tide five-year cumulative risk of developing HCC for patients with cirrhosis ranges between 5% and 30%, depending on aetiology, region or ethnicity, and stage of cirrhosis. 12, 14 The highest risks are observed for individuals with HCV infection, of Asian ethnicity, and with decompensated disease. 12, 14 Further, non-alcoholic fatty liver disease (NAFLD) -associated with obesity, insulin resistance, and type 2 diabetes -is an increasingly recognised risk factor for HCC in developed countries. 15, 16 The recently released Australian Cancer Incidence and Mortality books by the Australian Institute of Health and Welfare (AIHW) have, for the first time, provided incidence and mortality data for a broad range of cancers by states and territories.
The current study will extract data for primary liver cancers (no breakdown by type available), with the aim to i) assess temporal trends for incidence and mortality of liver cancer; ii) assess jurisdictional differences for liver cancer incidence and mortality; and iii) compare national incidence and mortality data for other types of cancers.
Methods
The Table 2 ).
For males, no joinpoints were identified, with an AAPC of 3.150% (95%CI 2.972-3.327) observed ( Figure 3 , supplementary file). For females, the AAPC was 3.597 (95%CI 3.314-3.880), with no joinpoints identified ( Figure 4 , supplementary file).
Jurisdictional trends for ASR incidence and mortality of liver cancer
ASR incidence for all persons in 2014 was higher for the Northern Territory (NT) (12.607/100,000 persons; 95%CI 7.339-17.867) than the national rate (7.396/100,000; 95%CI 7.069-7.723), however, the wide 95%CI for the NT indicates this difference was not statistically significant ( AAPCs ranging between 2.269% for the ACT and 3.963% for SA. For the NT, the AAPC for mortality was 0.692% (p=0.349) ( For all cancers combined, the ASR mortality rate decreased between 1982 and 2015, with an AAPC of -0.780, 95%CI -0.843--0.716). Negative AAPCs (indicating decreased mortality rates) were also observed for colorectal cancer (-2.302%, 95%CI -2.615--1.987), lung cancer (-0.999, 95%CI -1.128--0.869) and breast cancer (-1.425%, 95%CI -1.704--1.145). Between 1982 and 2015, the ASR mortality for melanomas of the skin increased, with an AAPC of 0.514% (95%CI 0.007-1.024). In contrast, the AAPC for liver cancer mortality was 3.013% (95%CI 2.448-3.581).
Discussion
This paper provides an overview of the increasing burden of liver cancer experienced in Australia over the past three decades. Since 1982, ASR incidence for liver cancer increased by an average of 4.858% annually, and mortality by 3.013% annually. Over the entire reporting period, ASR incidence increased by 306% and mortality by 184%. These results are in keeping with a recently published study by Wallace and colleagues. 3 This study used data from the Australian Cancer Database to assess incidence and survival trends for HCC between 1982 and 2014. The authors reported a slightly lower AAPC for ASR incidence of 4.46% (95%CI 4.24-4.69 cf. 4.858% (95%CI 4.558-5.159)), however, this analysis was limited to HCC cases. For ASR incidence by sex, Wallace and colleagues reported an AAPC of 4.33% (95%CI 4.09-4.57) for males and 4.21% (95%CI 3.81-4.60) for females, similar to our estimates: 4.597% (95%CI 4.387-4.808) for males, but slightly lower for females (5.089%, 95%CI 4.559-5.623). Our inclusion of all primary liver cancers and Wallace's focus on HCCs likely explains these differences, along with different approaches to coding of cases.
The key drivers of both the observed and projected increases in incidence of liver cancer have been discussed by several authors. [20] [21] [22] [23] These include an ageing population, increasing prevalence of metabolic syndrome, NAFLDs and type 2 diabetes, and increased migration from endemic HBV countries. 14,24-27 HCV infections have also been a key risk factor for HCC, however, the uptake of direct-acting antiviral treatments in Australia is expected to result in HCV becoming a less commonly observed risk factor. 3, 28 Universal vaccination for HBV, specifically for infants, is a cornerstone of the strategy to reduce prevalence, with 84% of infants globally having received a full schedule of vaccine doses as of 2015. 29 However, estimates suggest that globally, only 9% of HBV infected people have been diagnosed, and of this group, 8% have received antiviral treatment. 29 In the absence of treatment, the cumulative five-year incidence of cirrhosis for adults is 8-20%. 30 In turn, the annual risk for developing HCC for cirrhotic HBV patients is 2-8%. [31] [32] [33] The global burden of HBV and consequently HCC has been concentrated in developing countries, with >75% of HCC incidence occurring in Asian and subSaharan African countries. 34, 35 With increasing migration occurring globally, it is essential that countries experiencing changing demographics, such as Australia, respond accordingly to these health issues.
In concert with global increases in prevalence of obesity, are increased prevalence rates for NAFLD, largely driven by metabolic syndrome. 16 NAFLDs include conditions of increasing severity of liver injury: simple steatosis, non-alcoholic steatohepatitis (NASH), cirrhosis and complications of cirrhosis in the absence of competing etiologies. 16, 36 These disorders are considered to represent hepatic manifestations of metabolic syndrome. 36 A large review recently reported the annual incidence of HCC amongst NAFLD patients was 0.44 per 1,000 person years (95%CI 0.29-0.66) and more specifically, for NASH the annual incidence rate was 5.29 per 1,000 person years (95%CI 0.75-37.56). 16 Global prevalence of NAFLD has been estimated to be 25.24% (95%CI 22.10-28.65), 16 and prevalence often corresponds with rates of obesity. 25 Highest rates of NAFLD were reported for the Middle East (32%), South America (31%), Asia (27%), the USA (24%) and Europe (14%) -no data have been reported for the general Australian community. 16 With 63.4% of the adult Australian population overweight or obese, 37 studies are required to better understand the burden of NAFLD and NASH locally to inform responses.
Analysis of jurisdictional data showed that ASR incidence was highest in the NT (12.607/100,000 persons), VIC (8.229/100,000) and NSW (7.798/100,000). Accordingly, these states experience the highest burden of HBV and, with the exception of VIC, HCV. The National Notifiable Diseases Surveillance System provides estimates of unspecified (i.e. not incident) cases for HBV and HCV. In 2017, the rate of unspecified HBV infections was highest in NT (38.0/100,000), NSW (29.2/100,000) and VIC (27.5/100,000).
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For HCV unspecified cases, the rates were highest for the NT (59.0/100,000) and NSW (50.8/100,000).
The national incidence and mortality data presented in this paper are in stark contrast to the trends observed for the seven cancers with a greater burden of disease in Australia than liver cancer (lung, colorectal, breast, prostate, pancreatic, brain, melanomas of the skin) and for all cancers combined. Similar findings have been reported in other recently published papers 3, 4 showing that in the context of Australian cancer prevention and care programs, liver cancer is an outlier. 39 Two recommendations for surveillance for liver cancer have been published, both stating that people at high risk (albeit different definitions) of developing liver cancer should undergo six-monthly liver health checks, as prognosis is highly dependent on timing of diagnosis. 40, 41 However, the five-year survival rate of 18.5% 42 suggests most liver cancers are diagnosed late in their development, in the absence of regular surveillance. 43 National screening programs have contributed to improved outcomes for many patients. For example, BreastScreen Australia, which targets women aged 50-74 years, has contributed to a 32% decrease in mortality over the past two decades, and the National Cervical Screening Program has contributed to a 60% reduction in mortality since it commenced in 1991. 44 However, screening programs for cancer can carry risks, such as A strength of our study was use of national and jurisdictional data on cancer incidence and mortality. In Australia, notifications to cancer registries for most cancer diagnoses are legislated. The AIHW collates these data and has published more than three decades of incidence and mortality data for a range of cancers. An important limitation of this study is the potential for misclassification of cancer diagnoses. A study by Hong and colleagues 46 compared capture of HCC diagnoses by the Victorian Cancer Registry with data collected from several tertiary hospitals and other health service providers. They reported incidence from the hospitals/service providers was two-fold higher than reported from the Cancer Registry. This difference was largely due to the Registry's use of histology as a basis for classification, whereas the researchers used diagnostic criteria from the American Association for the Study of Liver Diseases (AASLD) for this. In response the Victorian Cancer Registry reassessed all liver cancer diagnoses for the 1982-2014 period using clinical diagnostic guidelines, thereby reducing or eliminating under-reporting. 4 As such, the data reported in this study, particularly for other jurisdictions, may reflect an underestimate of the true number of liver cancer cases.
Liver cancer has been a low-prevalence cancer in developed countries including Australia. The demographic changes and increasing prevalence of overweight and obesity will likely contribute to increases in incidence in coming decades. The poor survival rates associated with liver cancer further contribute to the need for a greater focus on reducing this burden of disease. While substantial advances are being made regarding immunotherapy treatments for liver cancer, early diagnosis will likely remain a key factor in prognosis for several years to come. Current Australian recommendations for HCC surveillance differ and should be synthesised so health practitioners have a clear understanding of surveillance. Novel approaches are required to increase uptake and adherence to surveillance among at-risk groups, including people who have migrated from endemic HBV countries.
